These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 21908036)

  • 1. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.
    Fayad ZA; Mani V; Woodward M; Kallend D; Abt M; Burgess T; Fuster V; Ballantyne CM; Stein EA; Tardif JC; Rudd JH; Farkouh ME; Tawakol A;
    Lancet; 2011 Oct; 378(9802):1547-59. PubMed ID: 21908036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
    Fayad ZA; Mani V; Woodward M; Kallend D; Bansilal S; Pozza J; Burgess T; Fuster V; Rudd JH; Tawakol A; Farkouh ME
    Am Heart J; 2011 Aug; 162(2):214-221.e2. PubMed ID: 21835280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
    Lüscher TF; Taddei S; Kaski JC; Jukema JW; Kallend D; Münzel T; Kastelein JJ; Deanfield JE;
    Eur Heart J; 2012 Apr; 33(7):857-65. PubMed ID: 22345126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study.
    Duivenvoorden R; Mani V; Woodward M; Kallend D; Suchankova G; Fuster V; Rudd JHF; Tawakol A; Farkouh ME; Fayad ZA
    JACC Cardiovasc Imaging; 2013 Oct; 6(10):1087-1094. PubMed ID: 24135322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H
    Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of change in carotid atherosclerotic plaque inflammation and burden as measured by 18-FDG-PET and MRI, respectively, in the dal-PLAQUE study.
    Mani V; Woodward M; Samber D; Bucerius J; Tawakol A; Kallend D; Rudd JH; Abt M; Fayad ZA
    Int J Cardiovasc Imaging; 2014 Mar; 30(3):571-82. PubMed ID: 24458953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
    Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
    Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does Vascular Calcification Accelerate Inflammation?: A Substudy of the dal-PLAQUE Trial.
    Joshi FR; Rajani NK; Abt M; Woodward M; Bucerius J; Mani V; Tawakol A; Kallend D; Fayad ZA; Rudd JH
    J Am Coll Cardiol; 2016 Jan; 67(1):69-78. PubMed ID: 26764069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dalcetrapib: turning the tide for CETP inhibition?
    Stroes ES; van Wijk DF
    Lancet; 2011 Oct; 378(9802):1529-30. PubMed ID: 21908039
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
    Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
    N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.
    Stein EA; Roth EM; Rhyne JM; Burgess T; Kallend D; Robinson JG
    Eur Heart J; 2010 Feb; 31(4):480-8. PubMed ID: 20097702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
    Rhainds D; Arsenault BJ; Brodeur MR; Tardif JC
    Future Cardiol; 2012 Jul; 8(4):513-31. PubMed ID: 22871191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study.
    Ballantyne CM; Miller M; Niesor EJ; Burgess T; Kallend D; Stein EA
    Am Heart J; 2012 Mar; 163(3):515-21, 521.e1-3. PubMed ID: 22424025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dalcetrapib: a review of Phase II data.
    Robinson JG
    Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial.
    Lo J; Lu MT; Ihenachor EJ; Wei J; Looby SE; Fitch KV; Oh J; Zimmerman CO; Hwang J; Abbara S; Plutzky J; Robbins G; Tawakol A; Hoffmann U; Grinspoon SK
    Lancet HIV; 2015 Feb; 2(2):e52-63. PubMed ID: 26424461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial.
    Ray KK; Ditmarsch M; Kallend D; Niesor EJ; Suchankova G; Upmanyu R; Anzures-Cabrera J; Lehnert V; Pauly-Evers M; Holme I; Štásek J; van Hessen MW; Jones P;
    Eur Heart J; 2014 Jul; 35(27):1792-800. PubMed ID: 24639426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib.
    Tardif JC; Dubé MP; Pfeffer MA; Waters DD; Koenig W; Maggioni AP; McMurray JJV; Mooser V; White HD; Heinonen T; Black DM; Guertin MC;
    Am Heart J; 2020 Apr; 222():157-165. PubMed ID: 32087417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation.
    Kastelein JJ; Duivenvoorden R; Deanfield J; de Groot E; Jukema JW; Kaski JC; Münzel T; Taddei S; Lehnert V; Burgess T; Kallend D; Lüscher TF
    Curr Med Res Opin; 2011 Jan; 27(1):141-50. PubMed ID: 21128879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes.
    Tardif JC; Rhainds D; Brodeur M; Feroz Zada Y; Fouodjio R; Provost S; Boulé M; Alem S; Grégoire JC; L'Allier PL; Ibrahim R; Guertin MC; Mongrain I; Olsson AG; Schwartz GG; Rhéaume E; Dubé MP
    Circ Cardiovasc Genet; 2016 Aug; 9(4):340-8. PubMed ID: 27418594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing.
    Derks M; Abt M; Mwangi A; Meneses-Lorente G
    Eur J Clin Pharmacol; 2010 Aug; 66(8):775-83. PubMed ID: 20521033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.